SCHEMBL3674399

SCHEMBL3674399

Clc1ccc(CSCc2ccc(Cl)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.63
CYP2C19 P33261 2/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2D6 P10635 2/20 0.55
ALDH1A1 P00352 4/20 0.55
LMNA P02545 2/20 0.55
IDO1 P14902 3/20 0.54
RAB9A P51151 3/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
MAPK1 P28482 2/20 0.50
NPC1 O15118 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
GFER P55789 1/20 0.49
HPGD P15428 2/20 0.47
CYP2A6 P11509 1/20 0.47
POLB P06746 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10614200 0.90 TDP1 (0.56) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL29738633 0.89 CYP1A2 (0.53) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL11232421 0.87 CYP1A2 (0.52) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL4639740 0.86 CYP1A2 (0.52) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL10062558 0.85 CYP1A2 (0.50) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL5976506 0.85 CYP1A2 (0.50) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL1082679 0.82 IDO1 (0.54) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL9214204 0.81 CYP2D6 (0.55) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL1148887 0.81 CYP1A2 (0.50) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL5977052 0.81 CYP1A2 (0.47) CYP1A2CYP2C19CYP2C9CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104230804-B The preparation method of chemiluminescent substance APS-5 key intermediate YUNNAN UNIVERSITY OF NATIONALITIES (CN) 2016-05-25 CN claimed
EP-0068294-B1 A NEW ACARICIDAL COMPOSITION, PROCESSES FOR ITS PRODUCTION AND ITS USE A. Nattermann & Cie. GmbH (DE) 1985-12-18 EP claimed
JP-8291133-A None JP disclosed
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2025-06-05 US disclosed
EP-4469046-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS Oulun Yliopisto (FI) 2024-12-04 EP disclosed
CN-114213294-B Method for synthesizing disulfide compound by using basic zeolite molecular sieve as catalyst 常州大学 2024-08-23 CN disclosed
US-11970694-B2 Rapid display method in translational synthesis of peptide PEPTIDREAM INC. (JP) 2024-04-30 US disclosed
CN-115010632-B Green synthesis method of mercaptan compounds 浙江大学衢州研究院 2023-09-01 CN disclosed
WO-2023144450-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2023-08-03 WO disclosed
CN-112321469-B Synthetic method of dibenzyl sulfide 成都理工大学 2022-07-12 CN disclosed
CN-111559976-B Synthetic method of heteroaryl thioether 扬州大学 2022-05-13 CN disclosed
US-4487966-A 3-Aminomethyl-1-(3-aminopropyl-1-methyl)-4-methylcyclohexane, a process for its preparation and its use BAYER AKTIENGESELLSCHAFT (DE) 1984-12-11 US disclosed
EP-0074561-B1 CYCLIC CETO-BUTYRALDEHYDES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF CYCLIC DIISOCYANATES BAYER AG (DE) 1984-11-21 EP disclosed
EP-0100479-A1 3-(Aminomethyl)-1-(3-aminopropyl-1-methyl)-4-methyl cyclohexane, process for its preparation and its use BAYER AG (DE) 1984-02-15 EP disclosed
EP-0074561-A2 Cyclic ceto-butyraldehydes, process for their preparation and their use in the preparation of cyclic diisocyanates BAYER AG (DE) 1983-03-23 EP disclosed
EP-0008763-B1 AMINOMETHYL-CYCLODODECANES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTICORROSIVES BAYER AG (DE) 1981-04-01 EP disclosed
US-4251462-A REACTING 1,5,9-CYCLODODECATRIENE WITH CARBON MONOXIDE AND HYDROGEN, REMOVING CATALYST, REACTING WITH HYDROGEN AND AMMONIA BAYER AKTIENGESELLSCHAFT (DE) 1981-02-17 US disclosed
EP-0008763-A1 Aminomethyl-cyclododecanes, a process for their preparation and their use as anticorrosives BAYER AG (DE) 1980-03-19 EP disclosed
US-4064139-A TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS, ANTI-PARKINSON'S DISEASE MERCK & CO., INC. (US) 1977-12-20 US disclosed
US-3954729-A FROM A SECONDARY AMINE, CARBONYL SULFIDE, AND AN ALKYL HALIDE IHARA CHEMICAL INDUSTRY CO., LTD. (JA) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS NAMPT, NADK, NQO1 CYP1A2 1297/4885CYP2C19 1061/4885CYP2C9 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.